BioSTAR® bioabsorbable septal repair implant

Expert Review of Medical Devices

Volumn 4, Issue 6, 2007, Pages 781-792

  Mullen, Michael J ^a   Devellian, Carol A ^b   Jux, Christian ^c  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b NMT Medical Inc   (United States)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Cardiac occluder; Congenital heart disease; Heart catheterization; Implants; Patent foramen ovale; PFO; Prostheses; Septal repair

Indexed keywords

BIOCOMPATIBILITY; BIODEGRADABLE IMPLANT; EROSION; FOREIGN BODY REACTION; HEART ATRIUM SEPTUM DEFECT; HEART CATHETERIZATION; HISTOINCOMPATIBILITY; HUMAN; INTERMETHOD COMPARISON; MIGRATION; POSTOPERATIVE COMPLICATION; REVIEW; SAFETY; SURGICAL TECHNIQUE; THROMBUS; TISSUE REACTION; TISSUE REPAIR; TREATMENT OUTCOME; WOUND HEALING; ARTICLE; CLINICAL TRIAL; HEART SEPTUM DEFECT; PATENT FORAMEN OVALE;

ABSORBABLE IMPLANTS; CLINICAL TRIALS AS TOPIC; FORAMEN OVALE, PATENT; HEART SEPTAL DEFECTS; HUMANS; WOUND HEALING;

EID: 37649006227     PISSN: 17434440     EISSN: 17452422     Source Type: Journal    
DOI: 10.1586/17434440.4.6.781     Document Type: Review

References (105)

1. Billinger K, Ostermayer S, Carminati M et al. HELEX septal occluder for transcatheter closure of patent foramen ovale: multicentre experience. EuroIntervention 1. 465-471 (2006).
2. Buscheck F, Stevert H, Kleber F et al. Patent foramen ovale using the premere device: the results of the CLOSEUP trial. J. Interv. Cardiol. 19(4), 328-333 (2006).
3. Meier JM, Berger A, Delabays A et al. Percutaneous closure of patent foramen ovale: head-to-head comparison of two different devices. EuroIntervention 1(1), 22-26 (2005).
4. Donti A, Giardini A, Salomone L, Formigari R, Picchio FM. Transcatheter patent foramen ovale closure using the premere PFO occlusion system. Catheter Cardiovasc. Interv. 68(5), 736-740 (2006).
5. Alaeddini J, Feghali G, Jenkins S et al. Frequency of atrial tachyarrhythmias following transcatheter closure of patent foramen ovale. J. Invasive Cardiol. 18(8), 365-368 (2006).
6. Hill SL, Berul CI, Patel HT et al. Early ECG abnormalities associated with transcatheter closure of atrial septal defects using the Amplatzer septal occluder. J. Interv. Card. Electrophysiol. 4(3), 469-474 (2000).
7. Kiblawi FM, Sommer RJ, Levchuck SG. Transcatheter closure of patent foramen ovale in older adults. Catheter Cardiovasc. Interv. 68(1), 136-142 (2006).
8. Post MC, Van Deyk K, Budts W. Percutaneous closure of a patent foramen ovale: single-centre experience using different types of devices and mid-term outcome. Acta cardiol. 60(5), 515-519. (2005).
9. Amin Z, Hijazi ZM, Bass JL et al. Erosion of Amplatzer septal occluder device after closure of secundum atrial septal defects: review of registry of complications and recommendations to minimize future risk. Catheter Cardiovasc. Interv. 63(4), 496-502 (2004).
10. Divekar A, Gaamangwe T, Shaikh N, Raabe M, Ducas J. Cardiac perforation after device closure of atrial septal defects with the Amplatzer septal occluder. J. Am. Coll. Cardiol. 45(8), 1213-1218 (2005).
11. Preventza O, Sampath-Kumar S, Wasnick J, Gold JP. Late cardiac perforation following transcatheter atrial septal defect closure. Ann. Thorac. Surg. 77(4), 1435-1437 (2004).
12. Sherman JM, Hagler DJ, Cetta F. Thrombosis after septal closure device placement: a review of the current literature. Catheter Cardiovasc. Interv. 63(4), 486-489 (2004).
13. Anzai H, Child J, Natterson B et al. Incidence of thrombus formation on the Cardio SEAL and the Amplatzer interatrial closure devices. Am. J. Cardiol. 93(4), 426-431 (2004).
14. Krumsdorf U, Ostermayer S, Billinger K et al. Incidence and clinical course of thrombus formation on atrial septal defect and patient foramen ovale closure devices in 1,000 consecutive patients. J. Am. Coll. Cardiol. 43(2), 302-309 (2004).
15. Lai DW, Saver JL, Araujo JA, Reidl M, Tobis J. Pericarditis associated with nickel hypersensitivity to the Amplatzer occluder device: a case report. Catheter Cardiovasc. Interv. 66(3), 424-426 (2005).
16. Wertman B, Azarbal B, Riedl M, Tobis J. Adverse events associated with nickel allergy in patients undergoing percutaneous atrial septal defect or patent foramen ovale closure. J Am. Coll. Caidiol. 47(6), 1226-1227 (2006).
17. Sigler M, Jux C. Biocompatibitity of septal defect closure devices. Heart 93(4), 444-449 (2006).
18. Colombo A, Karvouni E. Biodegradable stents: "fulfilling the mission and stepping away". Circulation 102(4), 371-373 (2000).
19. Waksman R. Update on bioabsorbable stents: from bench to clinical. J. Interv. Cardiol. 19(5), 414-421 (2006).
20. Ruge H, Wildhirt SM, Libera P et al. Images in cardiovascular medicine. Left atrial thrombus on atrial septal defect closure device as a source of cerebral emboli 3 years after implantation. Circulation 112(10), e130-e131 (2005).
21. Cotts T, Strouse PJ, Graziano JN. Late migration of a Sideris buttoned device for occlusion of atrial septal defect. Catheter Cardiovasc. Interv. 68(5), 754-757 (2006).
22. Solomon SB. The future of Interventional cardiology lies in the left atrium. Int. J. Cardiovasc. Intervent. 6(3-4), 101-106 (2004).
23. Rao PS. Summary and comparison of atrial septal defect closure devices. Curr. Interv. Cardiol. Rep. 2(4), 367-376 (2000).
24. Ebeid MR. Percutaneous catheter closure of secundum atrial septal defects: a review. J. Invasive Cardiol. 14(1), 25-31 (2002).
25. Sommer RJ. Patent foramen ovale: a primer for headache physicians. Headache Currents 3(2), 23-36 (2006).
26. Moore P, Feldman T, Mead H et al. Novel non-implant radiofrequency energy catheter closure of patent foramen ovale in swine. J. Am. Coll. Cardiol. 47(4), 249A (2006).
27. Sievert H, Fischer E, Heinisch C et al. Transcatheter closure of patent foramen ovale without an implant. initial clinical experience. Circulation 116(15), 1701-1706 (2007).
28. Schneider B, Bauer R. Is surgical closure of patent foramen ovale the gold standard for treating interatrial shunts? An echocardiographic follow-up study. J. Am. Soc. Echocardiog. 18(12), 1385-1391 (2005).
29. Homma S, Di Tullio MR, Sacco RL et al. Surgical closure of patent foramen ovale in cryptogenic stroke patients. Stroke 28(12), 2376-2381 (1997).
30. Patten BM. Developmental defects at the foramen ovale. Am. J. Pathol. 14, 135-161 (1938).
31. Gross P. The patency of the so-called 'anatomically open but functionally closed' foramen ovale. Am. Heart J. 10, 101-109 (1934).
32. Patten BM. The closure of the foramen ovale. Am. J. Anat. 48, 19-44 (1931).
33. Schroeckenstein RF, Wasenda GJ, Edwards JE. Valvular competent patent foramen ovale in adults. Minn. Med. 55(1), 11-13 (1972).
34. Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin. Proc. 59(1), 17-20 (1984).
35. Webster MW, Chancellor AM, Smith HJ et al. Patent foramen ovale in young stroke patients. Lancet 2(8601), 11-12 (1988).
36. Cabanes L, Mas JL, Cohen A et al. Atrial septal aneurysm and patent foramen ovale as risk factors for cryptogenic stroke in patients less than 55 years of age. A study using transesophageal echocardiography. Stroke 24(12), 1865-1873 (1993).
37. Lechat P, Mas JL, Lascault G et al. Prevalence of patent foramen ovale in patients with stroke. N. Engl. J. Med. 318(18), 1148-1152 (1988).
38. Anzola GP, Magoni M, Guindani M, Rozzini L, Dalla Volta G. Potential source of cerebral embolism in migraine with aura: a transcranial Doppler study. Neurology 52(8), 1622-1625 (1999).
39. Marshall AC, Lock JE. Structural and compliant anatomy of the patent foramen ovate in patients undergoing transcatheter closure. Am. Heart J. 140(2), 303-307 (2000).
40. Ho SY, McCarthy KP, Rigby ML. Morphological features pertinent to interventional closure of patent oval foramen. J. Interv. Cardial. 16(1), 33-38 (2003).
41. Topaz O, Edwards JE, Bojack-Mackey S, Titus JL. Aneurysm of fossa ovalis in adults: a pathologic study. Cardiovasc. Pathol. 12(4), 219-225 (2003).
42. El Said HG, McMahon CJ, Mullins CE et al. Patent foramen ovate morphology and impact on percutaneous device closure. Pediatr. Control. 26(1), 62-65 (2005).
43. Hara H, Virmant R, Ladich E et al. Patent foramen ovale: current pathology, pathophysiology, and clinical status. J. Am. Coll. Cardiol. 46(9), 1768-1776 (2005).
44. Lucas JF, Radtke WA, Bandisode VM, Fairbrother DL, Shirali GS. Characteristics of the interatrial communication in patients undergoing transcatheter device closure of atrial septal defects for cryptogenic stroke. Echocardiography (Mount Kisco, NY, USA 22(10), 814-817 (2005).
45. McMahon CJ, El Said HG, Mullins CE. Use of the transseptal puncture in transcatheter closure of long tunnel-type patent foramen ovale. Heart 88(2), E3 (2002).
46. Ruiz CE, Alboliras ET, Pophal SG. The puncture technique: A new method for transcatheter closure of patent foramen ovale. Catheter Cardiovasc. Interv. 53(3), 369-372 (2001).
47. Chintala K, Turner D, Leaman S et al. Use of balloon pull-through technique to assist in CardioSEAL device closure of patent foramen ovale. Catheter Cardiovasc. Interv. 60, 101-106 (2003).
48. Levine RA, Wayman AE, Dinsmore RE et al. Noninvasive tissue characterization: diagnosis of lipomatous hypertrophy of the atrial septum by nuclear magnetic resonance imaging. J. Am. Coll. Cardiol. 7(3), 688-692 (1986).
49. Zanchetta M, Rigatelli G, Pedon L et al. Role of intracardiac echocardiography in atrial septal abnormalities. J. Interv. Cardiol. 16(1), 63-77 (2003).
50. Mullen MJ, Hildick-Smith D, De Giovanni JV et al. BioSTAR Evaluation STudy (BEST): a prospective, multicenter, phase I clinical trial to evaluate the feasibility, efficacy, and safety of the BioSTAR bioabsorbable septal repair implant for the closure of atrial-level shunts. Circulation 114(18), 1962-1967 (2006).
51. Mas JL, Arquizan C, Lamy C et al. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N. Engl. J. Med. 345(24), 1740-1746 (2001).
52. Berthet K, Lavergne T, Cohen A et al. Significant association of atrial vulnerability with atrial septal abnormalities in young patients with ischemic stroke of unknown cause. Stroke 31(2), 398-403 (2000).
53. Meier B. Iatrogenic atrial septal defect, erosion of the septum primum after device closure of a patent foramen ovale as a new medical entity. Catheter Cardiovasc. Interv. 68(1), 165-168 (2006).
54. Cooke JC, Getman JS, Harper RW. Chiari network entanglement and I herniation into the left atrium by an atrial septal defect occluder device. J. Am. Soc. Echocardiog. 12(7), 601-603 (1999).
55. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch. Intern. Med. 159(8), 813-818 (1999).
56. Di Tullio M, Sacco RL, Gopal A, Mohr JP, Homma S. Patent foramen ovale as a risk factor for cryptogenic stroke. Ann. Intern. Med. 117(6), 461-465 (1992).
57. Kizer JR, Devereux RB. Clinical practice. Patent foramen ovale in young adults with unexplained stroke. N. Engl. J. Med. 353(22), 2361-2372 (2005).
58. Bridges ND, Hellenbrand W, Latson L et al. Transcatheter closure of patent foramen ovale after presumed paradoxical embolism. Circulation 86(6), 1902-1908 (1992).
59. Khairy P, O'Donnell CP. Landzberg MJ. Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromboemboli: a systematic review. Ann. Intern. Med. 139(9), 753-760 (2003).
60. Thanopoulos BV, Dardas PD, Karanasios E, Mezilis N. Transcatheter closure versus medical therapy of patent foramen ovale and cryptogenic stroke. Catheter Cardiovasc. Interv. 68(5), 741-746 (2006).
61. Harrer JU, Wessels T, Franke A et al. Stroke recurrence and its prevention in patients with patent foramen ovale. Can. J. Neurol. Sci. 33(1), 39-47 (2006).
62. Windecker S, Wahl A, Nedeltchev K et al. Comparison of medical treatment with percutaneous closure of patent foramen ovale in patients with cryptogenic stroke. J. Am. Coll. Cardiol. 44(4), 750-758 (2004).
63. Del Sette M, Angeli S, Leandri M et al. Migraine with aura and right-to-left shunt on transcranial Doppler: a case-control study. Cerebrovascular dis. 8(6), 327-330 (1998).
64. Wilmshurst PT, Nightingale S, Walsh KP, Morrison WL. Effect on migraine of closure of cardiac right-to-left shunts to prevent recurrence of decompression illness or stroke or for haemodynamic reasons. Lancet 356 (9242), 1648-1651 (2000).
65. Morandi E, Anzola GP, Angeli S, Melzi G, Onorato E. Transcatheter closure of patent foramen ovale: a new migraine treatment? J. Interv. Cardiol. 16(1), 39-42 (2003).
66. Schwerzmann M, Wiher S, Nedeltchev K et al. Percutaneous closure of patent foramen ovale reduces the frequency of migraine attacks. Neurology 62(8), 1399-1401 (2004).
67. Reisman M, Christofferson RD, Jesurum J et al. Migraine headache relief after transcatheter closure of patent foramen ovale. J. Am. Coll. Cardiol. 45(4), 493-495 (2005).
68. Azarbal B, Tobis J, Suh W et al. Association of interatrial shunts and migraine headaches: impact of transcatheter closure. J. Am. Coll. Cardiol. 45(4), 489-492 (2005).
69. Post MC, Thijs V, Herroelen L, Budts WI. Closure of a patent foramen ovale is associated with a decrease in prevalence of migraine. Neurology 62(8), 1439-1440 (2004).
70. Giardini A, Donti A, Formigari R et al. Transcatheter patent foramen ovale closure mitigates aura migraine headaches abolishing spontaneous right-to-left shunting. Am. Heart J. 151(4), 921-925 (2006).
71. Anzola GP, Frisoni GB, Morandi E, Casilli F, Onorato E. Shunt-associated migraine responds favorably to atrial septal repair: a case-control study. Stroke 37(2), 430-434 (2006).
72. Guerin P, Lambert V, Godart F et al. Transcatheter closure of patent foramen ovale in patients with platypnea-orthodeoxia: results of a multicentric French registry. Cardiovasc. Intervent. Radiol. 28(2), 164-168 (2005).
73. Cartoni D, De Castro S, Valente G et al. Identification of professional scuba divers with patent foramen ovale at risk for decompression illness. Am. J. Cardiol. 94(2), 270-273 (2004).
74. Torti SR, Billinger M, Schwerzmann M et al. Risk of decompression illness among 230 divers in relation to the presence and size of patent foramen ovale. Eur. Heart J. 25(12), 1014-1020 (2004).
75. Shanoudy H, Soliman A, Raggi P et al. Prevalence of patent foramen ovale and its contribution to hypoxemia in patients with obstructive sleep apnea. Chest 113(1), 91-96 (1998).
76. Beelke M, Angeli S, Del Sette M et al. Obstructive sleep apnea can be provocative for right-to-left shunting through a patent foramen ovale. Sleep 25(8), 856-862 (2002).
77. Beelke M, Angeli S, Del Sette M et al. Prevalence of patent foramen ovale in subjects with obstructive sleep apnea: a transcranial Doppler ultrasound study. Sleep Medicine 4(3), 219-223 (2003).
78. Agnoletti G, Iserin L, Lafont A, Sidi D, Desnos M. Obstructive sleep apnoea and patent foramen ovale: successful treatment of symptoms by percutaneous foramen ovale closure. J. Interv. Cardiol. 18(5), 393-395 (2005).
79. Johansson MC, Eriksson P, Peker Y et al. The influence of patent foramen ovale on oxygen desaturation in obstructive sleep apnoea. Eur. Respir. J. 29(1), 149-155 (2007).
80. Purandare N, Oude Voshaar RC, Burns A, Velupandian UM, McCollum C. Paradoxical embolization: a potential cause of cerebral damage in Alzheimer's disease? Neurological Res. 28(6), 679-684 (2006).
81. Klotzsch C, Sliwka U, Berlit P, Noth J. An increased frequency of patent foramen ovale in patients with transient global amnesia. Analysis of 53 consecutive patients. Arch. Neurol. 53(6), 504-508 (1996).
82. Asirdizer M, Tatlisumak E. The role of eustachian valve and patent foramen ovale in sudden death. J. Clin. Forensic Med. 13(5), 262-267 (2006).
83. Allemann Y, Hutter D, Lipp E et al. Patent foramen ovale and high-altitude pulmonary edema. JAMA 296(24), 2954-2958 (2006).
84. Hacievliyagil SS, Gunen H, Kosar FM, Sahin I, Kilic T. Prevalence and clinical significance of a patent foramen ovale in patients with chronic obstructive pulmonary disease. Resp. Med. 100(5), 903-910 (2006).
85. Soliman A, Shanoudy H, Liu J, Russell DC, Jarmukli NF. Increased prevalence of patent foramen ovale in patients with severe chronic obstructive pulmonary disease. J. Am. Soc. Echocardiog. 12(2), 99-105 (1999).
86. Giberti L, Bino G, Tanganelli P. Pregnancy, patent foramen ovale and stroke: a case of pseudoperipheral facial palsy. Neurol. Sci. 26(1), 43-45 (2005).
87. Agostoni P, Gasparini G, Destro G. Acute-myocardial infarction probably caused by paradoxical embolus in a pregnant woman. Heart 90(3), e12 (2004).
88. Engelhardt M, Folkers W, Brenke C et al. Neurosurgical operations with the patient in sitting position: analysis of risk factors using transcranial Doppler sonography. Br. J. Anaesth. 96(4), 467-472 (2006).
89. Forteza AM, Rabinstein A, Koch S et al. Endovascular closure of a patent foramen ovale in the fat embolism syndrome: changes in the embolic patterns as detected by transcranial Doppler. Arch. Neurol. 59(3), 455-459 (2002).
90. Marini C, Miniati M, Ambrosino N et al. Dyspnoea and hypoxaemia after lung surgery: the role of interatrial right-to-left shunt. Eur. Respir. J. 28(1), 174-181 (2006).
91. Djaiani G, Phillips-Bute B, Podgoreanu M et al. The association of patent foramen ovale and atrial fibrillation after coronary artery bypass graft surgery. Anesth. Analg. 98(3), 585-589 (2004).
92. Hausdorf G. StarFlex ASD closure: deployment, techniques, equipment. J. Interv. Cardiol. 14(1), 69-76 (2001).
93. Hausdorf G, Kaulitz R, Paul T, Carminati M, Lock J. Transcatheter closure of atrial septal defect with a new flexible, self-centering device (the STARFlex Occluder). Am. J. Cardiol. 84(9), 1113-1116, A1110 (1999).
94. Abraham GA, Murray J, Billiar K, Sullivan SJ. Evaluation of the porcine intestinal collagen layer as a biomaterial. J. Biomed. Mater. Res. 51(3), 442-452 (2000).
95. Billiar K, Murray J, Laude D, Abraham G, Bachrach N. Effects of carbodiimide crosslinking conditions on the physical properties of laminated intestinal submucosa. J. Biomed. Mater. Res. 56(1), 101-108 (2001).
96. Badylak SF. Xenogeneic extracellular matrix as a scaffold for tissue reconstruction. Transpl. Immunol. 12(3-4), 367-377 (2004).
97. Badylak SF, Tullius R, Kokini K et al. The use of xenogeneic small intestinal submucosa as a biomaterial for Achilles tendon repair in a dog model. J. Biomed. Mater. Res. 29(8), 977-985 (1995).
98. Huynh T, Abraham G, Murray J et al. Remodeling of an acellular collagen graft into a physiologically responsive neovessel. Nature biotechnol. 17(11), 1083-1086 (1999).
99. Rosen M, Roselli EE, Faber C et al. Small intestinal submucosa intracardiac patch: an experimental study. Surgical Innovation 12(3), 227-231 (2005).
100. Jux C, Wohlsein P, Bruegmann M et al. A new biological matrix for septal occlusion. J. Interv. Cardiol. 16(2), 149-152 (2003).
101. Jux C, Bertram H, Wohlsein P, Bruegmann M, Paul T. Interventional atrial septal defect closure using a totally bioresorbable occluder matrix: development and preclinical evaluation of the BioSTAR device. J. Am. Coll. Cardiol. 48(1), 161-169 (2006).
102. Bailey AJ. Perspective article: the fate of collagen implants in tissue defects. Wound Repair Regen 8(1), 5-12 (2000).
103. Everts V, van der Zee E, Creemers L, Beertsen W. Phagocytosis and intracellular digestion of collagen, its role in turnover and remodelling. Histochem. J. 28(4), 229-245 (1996).
104. Allman AJ, McPherson TB, Badylak SF et al. Xenogeneic extracellular matrix grafts elicit a TH2-restricted immune response. Transplantation 71(11), 1631-1640 (2001).
105. Martin D, Williams S. Medical applications of poly-4-hydroxybutyrate: a strong flexible absorbable biomaterial. Biochem. Eng. J. 16, 97-105 (2003).